Am. J. Respir. Crit. Care Med., Volume 162, Number 3, September 2000, 891-895

Trends in Pulmonary Function in Patients with Cystic Fibrosis Correlate with the Degree of Glucose Intolerance at Baseline

CARLOS E. MILLA, WARREN J. WARWICK, and ANTOINETTE MORAN

Cystic Fibrosis Center, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota

In patients with cystic fibrosis, CF-related diabetes mellitus (CFRD) has been associated with increased morbidity and mortality. Whether glucose intolerance is also associated with poor outcomes is unclear. To better define these relationships we prospectively followed a group of 152 patients with CF without diabetes for 4 yr. Patients were classified as having normal glucose tolerance (NGT), impaired glucose tolerance (IGT), or CFRD without fasting hyperglycemia (CFRD-No FH). FEV₁, FVC, and body mass index (BMI) were measured at baseline and quarterly. At baseline 45% of the patients had NGT, 38.8% had IGT, and 15.8% had CFRD-No FH. FEV₁, FVC, and BMI at baseline were comparable among these groups (all p > 0.1). After 4 yr an overall decline in FEV₁ and FVC occurred, with no change in BMI. The rates of decline for FEV₁ and FVC correlated with the glucose tolerance groups, with the highest rates of decline occurring among the CFRD-No FH group. In addition, patients in the lowest quartile for insulin production at baseline experienced the highest rates of pulmonary function decline over time, suggesting a relationship between insulin deficiency and clinical deterioration. We conclude that the degree of glucose intolerance is a strong determinant of future lung function decline in patients with CF.

This article has been cited by other articles:

				D. Peckham Routine screening for cystic fibrosis-related diabetes J R Soc Med, July 1, 2009; 102(Supplement_1): 36 - 39. [Full Text] [PDF]

				M. Walshaw Routine OGTT screening for CFRD - no thanks J R Soc Med, July 1, 2009; 102(Supplement_1): 40 - 44. [Full Text] [PDF]

				S. Tierney, K. Webb, A. Jones, M. Dodd, D. Mckenna, R. Rowe, J. Whitehouse, and C. Deaton Living with cystic fibrosis-related diabetes or type 1 diabetes mellitus: a comparative study exploring health-related quality of life and patients' reported experiences of hypoglycaemia Chronic Illness, December 1, 2008; 4(4): 278 - 288. [Abstract] [PDF]

				T. M. Kremer, R. G. Zwerdling, P. H. Michelson, and B. P. O'Sullivan Intensive Care Management of the Patient With Cystic Fibrosis J Intensive Care Med, May 1, 2008; 23(3): 159 - 177. [Abstract] [PDF]

				C. A. Merlo, M. P. Boyle, M. Diener-West, B. C. Marshall, C. H. Goss, and N. Lechtzin Incidence and Risk Factors for Multiple Antibiotic-Resistant Pseudomonas aeruginosa in Cystic Fibrosis Chest, August 1, 2007; 132(2): 562 - 568. [Abstract] [Full Text] [PDF]

				A Battezzati, P M Battezzati, D Costantini, M Seia, L Zazzeron, M C Russo, V Dacco, S Bertoli, A Crosignani, and C Colombo Spontaneous hypoglycemia in patients with cystic fibrosis Eur. J. Endocrinol., March 1, 2007; 156(3): 369 - 376. [Abstract] [Full Text] [PDF]

				C Que, P Cullinan, and D Geddes Improving rate of decline of FEV1 in young adults with cystic fibrosis Thorax, February 1, 2006; 61(2): 155 - 157. [Abstract] [Full Text] [PDF]

				B. J. Plant, C. G. Gallagher, R. Bucala, J. A. Baugh, S. Chappell, L. Morgan, C. M. O'Connor, K. Morgan, and S. C. Donnelly Cystic Fibrosis, Disease Severity, and a Macrophage Migration Inhibitory Factor Polymorphism Am. J. Respir. Crit. Care Med., December 1, 2005; 172(11): 1412 - 1415. [Abstract] [Full Text] [PDF]

				E. J. Sims, M. W. Green, and A. Mehta Decreased Lung Function in Female but not Male Subjects With Established Cystic Fibrosis-Related Diabetes Diabetes Care, July 1, 2005; 28(7): 1581 - 1587. [Abstract] [Full Text] [PDF]

				C. Mueller-Brandes, R. W. Holl, M. Nastoll, and M. Ballmann New criteria for impaired fasting glucose and screening for diabetes in cystic fibrosis Eur. Respir. J., April 1, 2005; 25(4): 715 - 717. [Abstract] [Full Text] [PDF]

				M. S. Stalvey Cystic fibrosis-related diabetes should not be trivialized AAP News, March 1, 2005; 26(3): 25 - 25. [Full Text] [PDF]

				R. L. Gibson, J. L. Burns, and B. W. Ramsey Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis Am. J. Respir. Crit. Care Med., October 15, 2003; 168(8): 918 - 951. [Abstract] [Full Text] [PDF]

				B. Philips and E. Baker Editorial III: Hyperglycaemia and the lung Br. J. Anaesth., April 1, 2003; 90(4): 430 - 433. [Full Text] [PDF]

				L Dobson, A T Hattersley, S Tiley, S Elworthy, P J Oades, and C D Sheldon Clinical improvement in cystic fibrosis with early insulin treatment Arch. Dis. Child., November 1, 2002; 87(5): 430 - 431. [Full Text] [PDF]

				B. S. Freeland and J. Micallef Cystic-Fibrosis-Related Diabetes Mellitus The Diabetes Educator, September 1, 2002; 28(5): 768 - 775. [PDF]

				M. J. TOBIN Pediatrics, Surfactant, and Cystic Fibrosis in AJRCCM 2000 Am. J. Respir. Crit. Care Med., November 1, 2001; 164(9): 1581 - 1594. [Full Text] [PDF]

				A. Moran, J. Phillips, and C. Milla Insulin and Glucose Excursion Following Premeal Insulin Lispro or Repaglinide in Cystic Fibrosis-Related Diabetes Diabetes Care, October 1, 2001; 24(10): 1706 - 1710. [Abstract] [Full Text] [PDF]

				A. Moran, C. Milla, R. Ducret, and K. S. Nair Protein Metabolism in Clinically Stable Adult Cystic Fibrosis Patients With Abnormal Glucose Tolerance Diabetes, June 1, 2001; 50(6): 1336 - 1343. [Abstract] [Full Text]

				K. Wallick, J. A. Nick, and D. M. Rodman Cystic Fibrosis Critical Care . No Longer an Oxymoron Am. J. Respir. Crit. Care Med., February 1, 2001; 163(2): 310 - 312. [Full Text]